Generative AI in Action: From Accelerating Drug Development to Enhancing Customer Insights and Operations
In episode 44, the conversation begins with an exploration of current generative AI trends and how they differ from traditional machine learning approaches. The episode highlights the innovative use of generative AI by companies like Pfizer and Takeda to accelerate drug development and clinical trials. It also features success stories from CogniSure and Comcast, focusing on enhancing customer insights and improving call center responses. The discussion continues with CMA CGM and Dick’s Sporting Goods leveraging AI for dynamic pricing and personalized marketing strategies. Insights from McKinsey and Accenture demonstrate how generative AI is streamlining operations. The episode concludes with a wrap-up of these transformative use cases.
Key Points
- Generative AI, paired with data analytics, enables companies to execute projects and solutions with unprecedented speed, as seen in the MIT Sloan Master of Business Analytics Capstone Project program.
- Biopharmaceutical companies like Pfizer and Takeda are using generative AI to reduce the time required for drug development and clinical trial design, significantly accelerating their processes.
- Companies such as Comcast and CMA CGM are leveraging generative AI to enhance real-time customer response and dynamic pricing, providing quicker and more accurate information to their customers.
Chapters
| 0:00 | |
| 0:34 | |
| 2:00 | |
| 3:34 | |
| 4:42 | |
| 5:53 | |
| 7:18 |
Transcript
Loading transcript...